The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Looking back at August 2023, several news items proved to be the most poured over by CancerNetwork® readers. This included 2 FDA approvals for patients with relapsed/refractory multiple myeloma, solutions for patients with breast cancer to conceive a child mid-treatment, details of the ongoing chemotherapy shortage, and a continuation of conversations from July’s Sarcoma Awareness Month.1-6
Full versions of the articles are referenced below in the order that they appear:
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.